Skip to main content

Table 2 Primary and secondary outcomes regarding laboratory values and clinical outcomes after surgery

From: Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial

Variable Group A Group B P value
Primary outcomes
 Total blood loss (mL)b 671.7 ± 352.7 915.8 ± 243.4 0.001
Secondary outcomes
  Postoperative transfusion
 Patients requiring transfusion 2 (3.33%) 2 (3.45%) 0.44
 Units transfused (IU) 3.5 4 NA
 Postop. laboratory values
 Hemoglobin (g/L)b
POD 1 115.3 ± 13.9 117.1 ± 11.6 0.55
POD 3 106.0 ± 10.9 99.7 ± 8.4 0.001
POD 14 123.8 ± 10.3 121.3 ± 8.1 0.13
 Hematocrit (%)b
POD 1 35.1 ± 4.2 35.7 ± 3.2 0.43
POD 3 32.3 ± 2.9 30.0 ± 2.5 0.001
POD 14 37.0 ± 4.5 36.4 ± 4.6 0.45
 FDP (mg/L)b
POD 1 13.7 ± 7.8 24.9 ± 11.3 0.001
POD 3 6.9 ± 3.4 12.0 ± 10.0 0.001
POD 14 4.4 ± 2.5 5.2 ± 2.4 0.083
 D-Dimer (mg/L)b
POD 1 4.6 ± 2.2 8.4 ± 8.0 0.001
POD 3 1.5 ± 1.1 3.3 ± 2.1 0.001
POD 14 1.2 ± 0.9 1.3 ± 0.5 0.22
Postop. knee function
 ROM (°)b
POD 1 99.7 ± 11.8 100.1 ± 11.7 0.58
POD 3 108.1 ± 4.9 107.4 ± 5.2 0.44
POD 14 110.9 ± 8.9 108.2 ± 9.4 0.11
PO 3 M 114.0 ± 7.0 113.7 ± 9.5 0.82
 KSS clinical scoreb
POD 3 48.2 ± 8.9 45.6 ± 8.5 0.32
POD 14 77.3 ± 6.4 75.2 ± 9.1 0.15
PO 3 M 82.8 ± 5.5 82.5 ± 4.3 0.73
 KSS function scoreb
POD 3 44.5 ± 10.6 43.1 ± 10.2 0.27
POD 14 68.6 ± 8.1 69.5 ± 8.4 0.53
PO 3 M 75.5 ± 5.6 76.7 ± 5.3 0.25
 Knee circumference (cm)b
POD 1 42.0 ± 3.7 43.8 ± 3.3 0.06
POD 3 43.1 ± 1.9 46.1 ± 3.7 0.001
POD 14 41.4 ± 2.9 44.9 ± 2.2 0.001
PO 3 M 41.1 ± 3.2 41.6 ± 3.0 0.28
 VAS pain scoreb
POD 1 3.8 ± 1.5 4.2 ± 2.0 0.26
POD 3 2.7 ± 0.8 2.9 ± 0.7 0.11
POD 14 2.2 ± 1.0 2.0 ± 0.8 0.32
PO 3 M 0.7 ± 0.9 0.6 ± 0.8 0.35
 Hospital stay (day)b 3.7 ± 1.2 4.0 ± 0.9 0.15